MARKET

IFRX

IFRX

Inflarx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.56
-0.47
-7.79%
After Hours: 5.56 0 0.00% 17:18 01/15 EST
OPEN
6.01
PREV CLOSE
6.03
HIGH
6.04
LOW
5.38
VOLUME
422.79K
TURNOVER
--
52 WEEK HIGH
9.70
52 WEEK LOW
2.520
MARKET CAP
145.15M
P/E (TTM)
-3.2226
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Lexicon Pharmaceuticals and NantKwest among healthcare gainers; Cassava Sciences among losers
Gainers: Organogenesis Holdings (ORGO) +33%. Lexicon Pharmaceuticals (LXRX) +30%. NantKwest (NK) +27%. Oragenics (OGEN) +25%. Bicycle Therapeutics (BCYC) +23%.Losers: Viveve Medical (VIVE) -23%. Cassava Sciences (SAVA) -12%. Timber Pharmaceuticals (TMBR) -11%. InflaRx
Seekingalpha · 4d ago
InflaRx Provides Update on Vilobelimab (IFX-1) Development
GlobeNewswire · 01/11 12:30
InflaRx to Present at Upcoming Annual J.P. Morgan Healthcare Conference
InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present virtually at the 39 Annual J.P. Morgan Healthcare Conference being held January 11-14, 2021.
GlobeNewswire · 01/07 12:30
InflaRx concludes enrollment in vilobelimab study in blood vessel inflammation disorder
InflaRx ([[IFRX]] +2.5%) has completed enrollment in the European Phase 2 IXCHANGE study of vilobelimab (IFX-1), in ANCA-associated vasculitis ((AAV)), a group disorders characterized by destruction and inflammation of small
Seekingalpha · 01/05 15:56
InflaRx Completes Enrollment in Vilobelimab (IFX-1) European Phase II Study in ANCA-associated Vasculitis
GlobeNewswire · 01/05 12:30
These 2 Penny Stocks Could Surge Over 200%, Says Raymond James
On Wall Street, it’s out with tech and mega-caps and in with small-caps, cyclicals and value. Investors have been rotating away from the big names that powered the market’s record-breaking charge forward since its March low on encouraging COVID-19 vaccine...
TipRanks · 12/08/2020 16:35
Hedge Funds Are Dumping InflaRx N.V. (IFRX)
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow nearly 817 active hedge funds and no...
Insider Monkey · 12/03/2020 01:30
Hedge Funds Are Dumping InflaRx N.V. (IFRX)
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow nearly 817 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]
Insider Monkey · 12/03/2020 01:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IFRX. Analyze the recent business situations of Inflarx through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IFRX stock price target is 9.70 with a high estimate of 14.92 and a low estimate of 3.482.
EPS
Institutional Holdings
Institutions: 57
Institutional Holdings: 5.19M
% Owned: 19.90%
Shares Outstanding: 26.11M
TypeInstitutionsShares
Increased
6
542.46K
New
13
-321.89K
Decreased
13
137.55K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About IFRX
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Inflarx NV stock information, including NASDAQ:IFRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IFRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IFRX stock methods without spending real money on the virtual paper trading platform.